Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by porksnifferon Mar 08, 2019 11:50am
133 Views
Post# 29461522

RE:New 3 Year Low Inevitable

RE:New 3 Year Low Inevitable
bigzig wrote: Just 25 cents above the 3 year low of $7.25 reached in 2016.

Should be an easy target for the Shorts, with Goldman now shorting 100,000 shares on a regular basis.

If the market correctly perceives Knight as a merchant bank which tend to trade at about 75% of Book, expect Knight to drop below $6.50.





Looks like it will be there in about a few hours. Totally disgraceful what's gone on here the past 2-3 years. Those thinking a proxy fight like this is good for a stock/company are in for a hard lesson. JRG has dropped the ball. Market is making him look like an amateur and his strategy a total failure. I am starting to believe that he's lost his way and is not sure what to do next. Wish he'd do the honurable thing and resign.
Bullboard Posts